Public Employees Retirement Association of Colorado Cuts Stock Position in Catalent, Inc. (NYSE:CTLT)

Public Employees Retirement Association of Colorado decreased its stake in shares of Catalent, Inc. (NYSE:CTLT) by 4.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,679 shares of the company’s stock after selling 793 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Catalent were worth $1,050,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC grew its holdings in shares of Catalent by 79.4% during the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after buying an additional 208 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the 2nd quarter worth $42,000. Mather Group LLC. purchased a new position in shares of Catalent in the first quarter worth $52,000. Longfellow Investment Management Co. LLC lifted its holdings in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after purchasing an additional 305 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CTLT. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Barclays raised their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, June 28th. StockNews.com started coverage on shares of Catalent in a research report on Wednesday, September 18th. They issued a “sell” rating for the company. Robert W. Baird reissued a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat, Catalent currently has a consensus rating of “Hold” and an average price target of $59.83.

Insiders Place Their Bets

In other Catalent news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the sale, the insider now directly owns 29,974 shares in the company, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,409 shares of company stock worth $782,923. Company insiders own 0.31% of the company’s stock.

Catalent Trading Up 0.7 %

Shares of CTLT stock opened at $60.14 on Wednesday. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20. The firm has a fifty day moving average price of $59.56 and a 200-day moving average price of $57.27. The company has a market cap of $10.88 billion, a price-to-earnings ratio of -9.86, a PEG ratio of 1.88 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.77.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.23 billion. As a group, equities analysts predict that Catalent, Inc. will post 1.06 earnings per share for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.